Stocks News

LAST PRICE
104.1200
TODAY'S CHANGE (%)
Trending Down-1.4400 (-1.3642%)

Bid / Lots
103.9900/ 4
Ask / Lots
104.2900/ 2
Open / Previous Close
106.4300 / 105.5600
Day Range
Low 101.8700
High 109.3700
52 Week Range
Low 43.8900
High 111.0200
Volume
336,768
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Today
- BPMC ONGOING INVESTIGATION UPDATE: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 55 minutes ago by Accesswire
  55 minutes ago by Accesswire
  Companies Mentioned: BPMC
  LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws.
- BPMC ONGOING INVESTIGATION UPDATE: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 56 minutes ago by Dow Jones
  56 minutes ago by Dow Jones
  Companies Mentioned: BPMC
  
  LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws.
Yesterday
- IMPORTANT ACTION UPDATE: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 11:25AM ET on Sunday Jun 02, 2024 by Accesswire
  11:25AM ET on Sunday Jun 02, 2024 by Accesswire
  Companies Mentioned: BPMC
  LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws.
- IMPORTANT ACTION UPDATE: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 11:25AM ET on Sunday Jun 02, 2024 by Dow Jones
  11:25AM ET on Sunday Jun 02, 2024 by Dow Jones
  Companies Mentioned: BPMC
  
  LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws.
Jun 1, 2024
- IMPORTANT ACTION ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 11:00AM ET on Saturday Jun 01, 2024 by Accesswire
  11:00AM ET on Saturday Jun 01, 2024 by Accesswire
  Companies Mentioned: BPMC
  LOS ANGELES, CA / ACCESSWIRE / June 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws.

May 30, 2024
- Viking Therapeutics to Participate at Upcoming Investor Conferences, from 4:03PM ET on Thursday May 30, 2024 by PR Newswire
  4:03PM ET on Thursday May 30, 2024 by PR Newswire
  Companies Mentioned: VKTX
May 29, 2024
- Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference, from 8:01AM ET on Wednesday May 29, 2024 by GlobeNewswire
  8:01AM ET on Wednesday May 29, 2024 by GlobeNewswire
  Companies Mentioned: ITCI
- Legend Biotech to Participate in the Jefferies Global Healthcare Conference, from 8:00AM ET on Wednesday May 29, 2024 by Business Wire
  8:00AM ET on Wednesday May 29, 2024 by Business Wire
  Companies Mentioned: LEGN
May 24, 2024
- HC Wainwright Adjusts Legend Biotech Price Target to $73 From $86, Maintains Buy Rating, from 8:11AM ET on Friday May 24, 2024 by MT Newswires
  8:11AM ET on Friday May 24, 2024 by MT Newswires
  Companies Mentioned: LEGN
- Deutsche Bank Starts Legend Biotech With Buy Rating, from 7:11AM ET on Friday May 24, 2024 by MT Newswires
  7:11AM ET on Friday May 24, 2024 by MT Newswires
  Companies Mentioned: LEGN
May 23, 2024
- Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA, from 5:00PM ET on Thursday May 23, 2024 by Business Wire
  5:00PM ET on Thursday May 23, 2024 by Business Wire
  Companies Mentioned: LEGN
- Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting, from 8:00AM ET on Thursday May 23, 2024 by GlobeNewswire
  8:00AM ET on Thursday May 23, 2024 by GlobeNewswire
  Companies Mentioned: ITCI
May 22, 2024
- MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program, from 10:33AM ET on Wednesday May 22, 2024 by MT Newswires
  10:33AM ET on Wednesday May 22, 2024 by MT Newswires
  Companies Mentioned: MXCT, LEGN
May 17, 2024
- Raymond James Upgrades Viking Therapeutics to Strong Buy From Outperform, from 7:30AM ET on Friday May 17, 2024 by MT Newswires
  7:30AM ET on Friday May 17, 2024 by MT Newswires
  Companies Mentioned: VKTX
May 14, 2024
- HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $87, Keeps Buy Rating, from 9:23AM ET on Tuesday May 14, 2024 by MT Newswires
  9:23AM ET on Tuesday May 14, 2024 by MT Newswires
  Companies Mentioned: LEGN

Blueprint Medicines Corp
NASDAQ:BPMCUnited States

Search Criteria

Today

BPMC ONGOING INVESTIGATION UPDATE: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 55 minutes ago by Accesswire

BPMC ONGOING INVESTIGATION UPDATE: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 56 minutes ago by Dow Jones

Yesterday

IMPORTANT ACTION UPDATE: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 11:25AM ET on Sunday Jun 02, 2024 by Accesswire

IMPORTANT ACTION UPDATE: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 11:25AM ET on Sunday Jun 02, 2024 by Dow Jones

Jun 1, 2024

IMPORTANT ACTION ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 11:00AM ET on Saturday Jun 01, 2024 by Accesswire

Peers Headlines

May 30, 2024

Viking Therapeutics to Participate at Upcoming Investor Conferences, from 4:03PM ET on Thursday May 30, 2024 by PR Newswire

May 29, 2024

Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference, from 8:01AM ET on Wednesday May 29, 2024 by GlobeNewswire

Legend Biotech to Participate in the Jefferies Global Healthcare Conference, from 8:00AM ET on Wednesday May 29, 2024 by Business Wire

May 24, 2024

HC Wainwright Adjusts Legend Biotech Price Target to $73 From $86, Maintains Buy Rating, from 8:11AM ET on Friday May 24, 2024 by MT Newswires

Deutsche Bank Starts Legend Biotech With Buy Rating, from 7:11AM ET on Friday May 24, 2024 by MT Newswires

May 23, 2024

Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA, from 5:00PM ET on Thursday May 23, 2024 by Business Wire

Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting, from 8:00AM ET on Thursday May 23, 2024 by GlobeNewswire

May 22, 2024

MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program, from 10:33AM ET on Wednesday May 22, 2024 by MT Newswires

May 17, 2024

Raymond James Upgrades Viking Therapeutics to Strong Buy From Outperform, from 7:30AM ET on Friday May 17, 2024 by MT Newswires

May 14, 2024

HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $87, Keeps Buy Rating, from 9:23AM ET on Tuesday May 14, 2024 by MT Newswires